Chemotherapy schedule
| Course . | Drug . | Daily dose . | Schedule . |
|---|---|---|---|
| Prophase (days 1-5) | Cyclophosphamide | 200 mg/m2 | Days 1 and 2 |
| Dexamethasone | 5 mg/m2 | Days 1 and 2 | |
| 10 mg/m2 | Days 3-5 | ||
| Triple intrathecal | Age based | Day 1 | |
| Cycles 1, 3, and 5 | Brentuximab vedotin* | 1.8 mg/kg | Day 1 |
| Methotrexate | 3 g/m2 over 3 h | Day 1 | |
| Dexamethasone | 10 mg/m2 | Days 1-5 | |
| Ifosfamide | 800 mg/m2 | Days 1-5 | |
| Etoposide | 100 mg/m2 | Days 4 and 5 | |
| Cytarabine | 150 mg/m2 × 2 | Days 4 and 5 | |
| Cycles 2, 4, and 6 | Brentuximab vedotin* | 1.8 mg/kg | Day 1 |
| Methotrexate | 3 g/m2 over 3 h | Day 1 | |
| Dexamethasone | 10 mg/m2 | Days 1-5 | |
| Cyclophosphamide | 200 mg/m2 | Day 1-5 | |
| Doxorubicin | 25 mg/m2 | Days 4 and 5 |
| Course . | Drug . | Daily dose . | Schedule . |
|---|---|---|---|
| Prophase (days 1-5) | Cyclophosphamide | 200 mg/m2 | Days 1 and 2 |
| Dexamethasone | 5 mg/m2 | Days 1 and 2 | |
| 10 mg/m2 | Days 3-5 | ||
| Triple intrathecal | Age based | Day 1 | |
| Cycles 1, 3, and 5 | Brentuximab vedotin* | 1.8 mg/kg | Day 1 |
| Methotrexate | 3 g/m2 over 3 h | Day 1 | |
| Dexamethasone | 10 mg/m2 | Days 1-5 | |
| Ifosfamide | 800 mg/m2 | Days 1-5 | |
| Etoposide | 100 mg/m2 | Days 4 and 5 | |
| Cytarabine | 150 mg/m2 × 2 | Days 4 and 5 | |
| Cycles 2, 4, and 6 | Brentuximab vedotin* | 1.8 mg/kg | Day 1 |
| Methotrexate | 3 g/m2 over 3 h | Day 1 | |
| Dexamethasone | 10 mg/m2 | Days 1-5 | |
| Cyclophosphamide | 200 mg/m2 | Day 1-5 | |
| Doxorubicin | 25 mg/m2 | Days 4 and 5 |
Brentuximab vedotin was given prior to any other chemotherapy on day 1.